Currently Enrolling Alzheimer's Disease Studies
Alzheimer's Disease is the 6th leading cause of death, and the only cause amongst the top 10 that cannot be prevented or cured. Because of this, it should be clear that new and innovative treatments for Alzheimer's are not just important - they're a necessity. Find out more about the treatments being pioneered at Princeton Medical Institute.
Study 1 - Sponsored by Merck
Who?: The researchers at Princeton Medical Institute are seeking men and women aged >50 years. Participants must have a family member or caregiver who can attend appointments during study visits. Other criteria for eligibility will be discussed with interested persons, without obligation, when calling the telephone number listed below. All study related visits, laboratory work, study medication, and all study related procedures including physical exams are provided at no cost. Qualified participants will receive compensation for time and travel.
What?: A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer's disease
What?: A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer's disease